New Acronis CyberApp Standard Accelerates Ecosystem Growth and Partner Success
Innovative CyberApp Standard invites new vendors to curate solutions for the Acronis ecosystem, unlocking more partner sales opportunities
SCHAFFHAUSEN, Switzerland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Acronis, the global leader in cyber protection, today announced the Acronis CyberApp Standard a groundbreaking integration technology. This innovation broadens the Acronis ecosystem to third-party vendors, offering them the means to seamlessly integrate their products and services into Acronis Cyber Protect Cloud, equipping service providers with essential tools necessary to drive efficiency and profitability.
Acronis CyberApp Standard is the only framework that allows vendors to deeply integrate into the Acronis platform with natively incorporated vendor workloads, alerts, widgets, and reports. This ensures a unified user experience for Acronis-owned and integrated applications, enhancing efficiency and reducing errors. Acronis CyberApp Standard offers vendors a unique, no-touch digital experience and complete application lifecycle management, unlike other platforms. Vendors interested in becoming part of the Acronis ecosystem gain access to the versatile Vendor Portal. It empowers them to build applications, share application details, upload marketing materials, and publish directly to the Acronis Application Catalog.
"Service providers require seamless integration between tools to stay agile and competitive. These integrations allow them to save time and resources on managing multiple tools and reduce the risk of human errors," said Gaidar Magdanurov, President at Acronis. "We are excited to make the CyberApp Standard available to all vendors and open up the Acronis partner ecosystem with over 20,000 service providers and millions of business customers. CyberApp creates an opportunity for vendors to acquire new customers and increase their profits while reinforcing cyber protection and service provider tools on the Acronis platform."
With the Acronis CyberApp Standard, technology vendors unlock sales and marketing opportunities with the ability to access over 100 distributors and 50,000 channel partners. Benefiting from accelerated time-to-market for integrated solutions, the Acronis ecosystem significantly reduces complexity and leverages more than 50 data centers, enabling vendors to deliver solutions compliant with various local regulations.
“A comprehensive technology ecosystem is a critical success factor to meeting the diverse needs of small, medium, and large MSPs. Innovative integration technology, such as CyberApp Standard, can help deliver a better experience for service providers who have diverse software integration requirements,” said Phil Goodwin, Research Vice President at IDC. “Integrations can encompass endpoint security, network management, and SaaS administration for end-customers while streamlining operational efficiency for service providers.”
Technology vendors can benefit from partnering with Acronis by joining the #CyberFit Technology Partner Program and working together on joint sales and marketing opportunities. The program enables partners to collaborate on go-to-market strategies, co-branded campaigns and product assets, marketing and sales guidance, and access to MDF funds.
“Our Partnership with Acronis has been monumental,” said Nikki Meyer, Corporate Vice President of Vendor Experience at Pax8. “Together, we empower managed service providers (MSPs) to scale their business by consolidating and automating industry-leading solutions. CyberApp Standard creates a seamless integration with any technology, which allows us to position these products as a better-together bundle. Our Partnership helps MSPs to meet and exceed their clients' needs by offering hundreds of natively integrated solutions in a single user interface.”
Acronis Cyber Protect Cloud is a comprehensive solution that combines backup and data recovery, cybersecurity, management, and automation built on the Acronis platform. The Acronis ecosystem portfolio includes more than 200 third-party products and services including LastPass, Rewst, SendMarc, Canauri, Infima Security, and Autobahn Security.
"The Acronis platform helps us automate our workflows, ensuring all steps are completed consistently," said Josh Aaronson, Director of Operations at HOCS. "The result is exponential time savings as there is no need to jump from console to console."
Partners interested in learning more are invited to attend the Acronis CyberApp Build event on Tuesday, October 24, 2023, at 11:00am EDT/ 3:00pm GMT, visit https://acronis.events/event/acronis-cyberapp-build/ to register.
For more information, visit: https://developer.acronis.com/.
Acronis unifies data protection and cybersecurity to deliver integrated, automated cyber protection that solves the safety, accessibility, privacy, authenticity, and security (SAPAS) challenges of the modern digital world. With flexible deployment models that fit the demands of service providers and IT professionals, Acronis provides superior cyber protection for data, applications, and systems with innovative next-generation antivirus, backup, disaster recovery, and endpoint protection management solutions powered by AI. With advanced anti-malware powered by cutting-edge machine intelligence and blockchain based data authentication technologies, Acronis protects any environment - from cloud to hybrid to on premises - at a low and predictable cost.
Acronis is a Swiss company, founded in Singapore. Celebrating two decades of innovation, Acronis has more than 2,000 employees in 45 locations. Acronis Cyber Protect solution is available in 26 languages in over 150 countries and is used by 20,000 service providers to protect over 750,000 businesses.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t